14,90
|
www.fiercebiotech.com/biotech/...estones-to-medigene-tcr-pact
...“We value Medigene's TCR technology platform, which enables us to tackle intracellular tumor antigens not addressable by CAR-Ts," bluebird CSO Philip Gregory, Ph.D., said in a statement. "Our expanded collaboration will help us broaden our pipeline of TCR lead candidates for potential future clinical development."
Medigene will handle the discovery of the TCRs before them passing off to bluebird, which will manage all preclinical and clinical development. Bluebird will hold exclusive licenses for the TCRs.
The backloaded nature of the deal means the near-term financial impact on Medigene is slight. But the original and revised deals are nonetheless landmarks in the German biotech’s attempt to position itself as a TCR specialist.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
19 | 11.771 | Medigene - Kurse/Quatschen/Charts/Einzeiler..u.s.w. | RichyBerlin | verstehnix | 21.01.25 10:10 | |
63 | 20.038 | Medigene - Sachliche und fachliche Beiträge | starwarrior03 | aefu | 16.01.25 11:06 | |
3 | 72 | Medigen Anstieg nur heisse Luft ? | Byblos | nahkauf | 23.12.24 20:45 | |
8 | Ab jetzt 1000 % - Der ultimative Talk | Justachance | Terminator9 | 06.09.24 09:42 | ||
Medigene - Neubewertung contra Rohrkrepierer | amarant | 30.04.24 19:57 |